Back to Search
Start Over
Emergence and evolution of TP53 mutations are a key feature of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- Source :
- Haematologica, Haematologica, Ferrata Storti Foundation, 2018, Epub ahead of print. ⟨10.3324/haematol.2017.181404⟩, Haematologica, 2018, Epub ahead of print. ⟨10.3324/haematol.2017.181404⟩
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- The cytogenetic anomaly of isolated del(5q) characterizes a subgroup of patients with lower-risk myelodysplastic syndrome (MDS). In the 2016 World Health Organization classification, one additional karyotypic abnormality (except −7 or del7q) can be present in such patients.[1][1] Median survival
- Subjects :
- 0301 basic medicine
Oncology
Male
medicine.medical_specialty
Karyotypic abnormality
[SDV.CAN]Life Sciences [q-bio]/Cancer
Tp53 mutation
Lower risk
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Medicine
Humans
TP53
Online Only Articles
Lenalidomide
ComputingMilieux_MISCELLANEOUS
Laboratory Hematology
business.industry
Myelodysplastic syndromes
Disease progression
Hematology
Middle Aged
Key features
medicine.disease
Prognosis
3. Good health
030104 developmental biology
030220 oncology & carcinogenesis
Myelodysplastic Syndromes
Mutation
Disease Progression
Chromosomes, Human, Pair 5
Female
Chromosome Deletion
Tumor Suppressor Protein p53
business
Median survival
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 03906078 and 15928721
- Database :
- OpenAIRE
- Journal :
- Haematologica, Haematologica, Ferrata Storti Foundation, 2018, Epub ahead of print. ⟨10.3324/haematol.2017.181404⟩, Haematologica, 2018, Epub ahead of print. ⟨10.3324/haematol.2017.181404⟩
- Accession number :
- edsair.doi.dedup.....19b95e1b69bdd5ab353c2061d4d541c8
- Full Text :
- https://doi.org/10.3324/haematol.2017.181404⟩